ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1375 National Cancer Institute Html en Cancer Screening Overview (PDQ®)–Health Professional Version Information about measuring the effectiveness of cancer screening tests and about weighing the strength of the evidence obtained from cancer screening research studies.
PDQ Screening0.435302
cancer antigen0.351044
cancer screening interventions0.511292
advanced-stage pancreatic cancer0.361147
cancer screening0.938139
lung cancer screening0.519031
new screening test0.500274
cancer prevention0.350991
Interval cancer events0.364348
new screening modality0.453389
IIIB–IV lung cancer0.361117
prostate screening0.417963
lung cancer rates0.355466
prostate cancer treatment0.3549
mammography screening0.457867
screening program0.415447
screening summaries0.435473
disease-specific mortality0.409334
cancer cases0.346604
whole-body screening technologies0.500642
lower cancer risk0.359738
interval cancer rates0.358328
colorectal cancer0.351483
routine cancer screening0.555956
recent screening0.436851
false-negative screening test0.511207
older screening modalities0.448481
breast cancer0.418358
cancer diagnosis0.374736
prostate cancer screening0.551218
actual cancer risk0.422669
cancer screening tests0.659235
randomized controlled trial0.36573
prostate cancer mortality.0.348853
false-positive screening results0.509129
screening center0.444606
fecal occult blood0.356414
higher cancer risk0.360321
cancer mortality.0.353113
decision making0.410621
all-cause mortality0.362129
breast cancer overdetection0.35093
routine screening mammographies0.474709
randomized clinical trials0.34952
Cancer Screening Trial0.566983
invasive diagnostic procedures0.355819
routine PSA screening0.472621
CLICK HERE
1456 National Cancer Institute Html en Vulvar Cancer Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of vulvar cancer.
lesion-type VIN grade0.488217
radiation therapy arm0.777718
vulvar surgical procedures0.466679
sentinel node dissection0.727156
Radiation Therapy section0.586061
case series0.468674
groin dissection study0.616489
vulvar cancer0.538035
positive sentinel nodes0.479331
lymph node dissection0.680638
sentinel node identification.0.538816
invasive vulvar cancer0.471336
vulvar cancer-related deaths0.462293
radiation therapy issue0.483522
clinically localized vulvar0.482117
node dissection0.932807
bloc inguinal node0.506403
sentinel node dissections0.642236
bilateral groin node0.587002
Actuarial groin recurrence0.544605
groin lymph0.484094
pelvic node resection0.498834
radical vulvectomy0.489162
sentinel node0.79935
high-grade vin0.507503
bilateral dissection0.465866
groin dissection arm0.620835
invasive locoregional vulvar0.48636
sentinel node procedures0.539343
groin recurrence0.545931
groin dissection0.6467
femoral lymph node0.521493
negative sentinel node0.528158
negative sentinel nodes0.475577
patients0.605395
groin-node dissection0.464
inguinal node dissection0.663124
groin node dissection0.784008
ipsilateral inguinal node0.504912
pelvic radiation0.458909
Node metastases0.461128
groin node-positive disease0.523738
groin radiation0.532254
regional lymph nodes0.463891
HPV 6/11-associated vulvar0.461386
negative groin nodes0.546977
systematic literature review0.508112
CLICK HERE
1499 National Cancer Institute Html en Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of paranasal sinus and nasal cavity cancer.
hemiparanasal sinus0.501642
cure rates0.493854
positive nodes0.488668
standard treatment schedules0.549584
Nodal involvement0.497639
cancer deaths0.490757
small percentage0.485324
paranasal sinuses0.76526
operable tumors0.521562
PDQ cancer information0.674275
(es).0.507032
T1 mucosal carcinomas0.579667
neck radiation therapy0.604078
cancer information summary0.645943
frequent type0.494315
high doses0.481624
Squamous cell carcinoma0.582109
breast cancer prevention0.543533
direct extension0.48751
malignant degeneration0.512598
advanced carcinomas0.493525
ethmoid sinuses0.558752
NCI’s PDQ0.512104
NCI PDQ cancer0.582736
paranasal sinus cancers0.63814
radical surgery0.487234
frontal sinuses0.560784
radiation therapy0.931486
low-grade benign tumor0.581394
maxillary sinus0.511122
locoregional recurrence accounts0.563108
nasal vestibule0.506572
Lymph nodes0.492664
vital areas0.483188
distant metastases0.516432
bony confines0.499241
malignant tumor0.600994
PDQ documents0.510902
early tumors0.514544
radical radiation therapy0.591316
advanced disease0.493565
nasal cavity0.593061
treatment volume0.481814
local disease0.484616
tumors0.539577
stage III tumors0.513203
neck cancer0.495811
postoperative radiation therapy0.591777
adjacent structures.0.488857
CLICK HERE
1553 National Cancer Institute Html en Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.
cancer treatment0.41722
Burkitt-like non-Hodgkin lymphoma0.414505
panniculitis-like T-cell lymphoma0.407586
mediastinal B-cell lymphoma0.477834
type0.421123
body0.397298
childhood non-hodgkin lymphoma0.888605
PDQ cancer information0.389516
Non-Hodgkin Lymphoma Treatment0.431482
clinical trial search0.395907
B-cell non-Hodgkin lymphoma0.444319
gamma-delta T-cell lymphoma0.40789
clinical trials0.596027
large cell lymphoma0.576342
peripheral t-cell lymphoma0.4403
clinical trial0.545942
stem cell transplant0.416614
Burkitt lymphoma0.412037
anaplastic lymphoma kinase0.405034
primary mediastinal b-cell0.402494
diffuse large b-cell0.419339
lymph nodes0.504405
Pediatric-type follicular lymphoma0.401311
large B-cell lymphoma0.505692
radiation therapy0.400696
childhood hodgkin lymphoma0.422956
treatment0.602592
Hodgkin Lymphoma Treatment0.428936
cutaneous t-cell lymphoma0.531706
cancer cells0.482982
Burkitt-like lymphoma /leukemia0.41493
HIV-related non-Hodgkin lymphoma0.410943
certain gene changes0.416336
Adult Non-Hodgkin Lymphoma0.452762
recurrent lymphoblastic lymphoma0.388804
lymphoblastic lymphoma0.418163
follicular lymphoma0.416701
combination chemotherapy0.479578
non-hodgkin lymphoma0.995932
bone marrow0.469909
marginal zone lymphoma0.455485
cells0.53075
cancer clinical trials0.407298
lymph node0.390457
treatment options0.51667
anaplastic large cell0.523091
HIV-associated non-Hodgkin lymphoma0.431952
cancer0.673011
CLICK HERE
1559 National Cancer Institute Html en Endometrial Cancer Screening (PDQ®)–Patient Version Expert-reviewed information summary about tests used to detect or screen for endometrial cancer.
cancer treatment0.561966
Pap test results0.564545
ongoing clinical trials0.564273
following PDQ summaries0.605267
PDQ cancer information0.713937
false-negative test result0.559289
Uterine Sarcoma Treatment0.562863
uterus0.565825
Endometrial sampling0.614718
clinical trials0.686375
test result0.59341
transvaginal ultrasound0.592257
cancer information summary0.653614
clinical trial0.570758
test results0.593938
breast cancer prevention0.577475
false-positive test result0.559048
latest published information0.566054
PDQ® Screening0.557798
NCI’s PDQ0.572282
cancer symptoms0.57367
NCI PDQ cancer0.624163
tests0.615659
black women0.581998
PDQ Screening0.598441
treatment0.572654
cancer prevention0.577647
screening tests0.574176
cancer cells0.559463
endometrial cancer screening0.701539
Cancer Information Service0.589993
Prevention Editorial Board0.603972
treatment clinical trials0.562297
National Cancer Institute0.661886
endometrial cancer0.979643
PDQ documents0.56725
new treatment0.567011
Cancer screening trials0.628138
Cancer Care page0.581539
PDQ database0.570002
breast cancer0.579583
abnormal vaginal bleeding0.663193
non-polyposis colon cancer0.588586
risk factor0.558033
PDQ summary0.615448
yearly screening0.56313
cancer information summaries0.594869
comprehensive cancer information0.595413
CLICK HERE
1617 National Cancer Institute Html en Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms.
red blood cells0.746761
chronic idiopathic myelofibrosis0.40092
cancer treatment0.416363
primary myelofibrosis0.53957
PDQ cancer information0.430215
bone marrow aspiration0.385705
clinical trial search0.421224
white blood cells0.676519
chronic eosinophilic leukemia0.451961
blood cells increases0.444984
clinical trials0.768861
chronic neutrophilic leukemia0.40279
mature blood cells0.434847
fewer blood cells0.406923
cancer information summary0.401424
clinical trial0.500574
early signs0.377313
patients0.431687
blood cells0.902472
blood vessels0.37721
chronic myelogenous leukemia0.406738
Treatment Editorial Board0.377482
essential thrombocythemia0.420345
treatment0.55278
stored stem cells0.37624
immature blood cells0.399031
blood stem cell0.37725
cancer cells0.408902
-fighting blood cells0.405086
lymphoid stem cell0.374191
specific cancer cells0.392312
chronic myeloproliferative neoplasms0.69658
signs0.38226
polycythemia vera0.418683
patient0.388228
treatment clinical trials0.396123
blood stem cells0.497004
National Cancer Institute0.457233
routine blood test0.45249
new treatment0.393316
white blood cell0.399685
extra blood cells0.469808
bone marrow0.605562
PDQ summary0.382577
cancer clinical trials0.425229
blood clots0.392843
cancer0.517448
information0.439199
Myelogenous Leukemia Treatment0.387746
CLICK HERE
1836 National Cancer Institute Html es Tratamiento de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento de la leucemia mieloide aguda infantil, síndromes mielodisplásicos y otras neoplasias mieloproliferativas.
frecuencia mutaciones0.438095
LMA familiares0.551304
leucemia eritroidea aguda0.449843
American Academy0.418016
Leucemia aguda eritroidea0.453243
gen runx1t10.417024
neoplasias mieloides0.421266
transient leukemia0.421355
Sin embargo0.442991
gen crebbp0.417273
LMA ayuda0.492779
necesarias mutaciones0.436351
leucemia mielomonocítica aguda0.45265
Panmielosis aguda0.424398
subtipo fab0.419671
leucemias mieloides0.437133
Leucemia basofílica aguda0.453074
leucemia mielógena0.434701
Children's Oncology Group0.430324
gen etv60.41685
leucemia transitoria0.433759
reordenamiento leucemia aguda0.452795
Leucemia megacarioblástica aguda0.453115
Smith MA0.431884
Leucemia aguda mielomonocítica0.453529
gen evi10.417889
leucemia promielocítica aguda0.56535
Organización Mundial0.42957
gen mll0.697325
células madre0.41719
leucemia aguda0.953312
LMA M00.546818
leucemia linfoblástica aguda0.491741
SAI Leucemia0.451225
tipo ii0.459931
gen runx10.418208
Pediatr Blood Cancer0.433879
gen cbf-beta0.418127
M0 LMA0.495335
leucemia monocítica aguda0.501087
fraterno presente leucemia0.436812
linaje mieloide0.448127
leucemias bifenotípicas mieloides0.422616
leucemia megacariocítica aguda0.525006
leucemia mieloblástica aguda0.537614
BCR-ABL1 Leucemia aguda0.451622
leucemia mieloide aguda0.756372
linaje linfoide0.423692
La traslocación0.522981
CLICK HERE
2002 National Cancer Institute Html es Tratamiento del feocromocitoma y paraganglioma (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del feocromocitoma y paraganglioma.
associated with0.440801
paraganglioma hereditario sdhd0.442898
Surg Oncol Clin0.439027
Gimenez-Roqueplo AP0.438768
Chatellier G0.438739
patients with apparently0.435891
with von hippel-lindau0.426826
evaluation following resection0.43956
gastric stromal sarcoma0.435317
Carney JA0.479643
hereditary paraganglioma0.424404
gland scaled score0.43937
Clin Proc0.426209
effective treatment with0.472522
secondary hypertension0.431368
Neuroendocrine Neoplasias0.453768
extra-adrenal paraganglioma0.447147
von hippel-lindau0.471522
feocromocitoma síndrome0.499112
patients with0.828258
Clin Endocrinol Metab0.986823
Young WF Jr0.474746
or secreting0.439481
Servais A0.436374
patients with metastatic0.46137
Surg Pathol0.438013
hypertension persistence after0.484322
adrenal gland scaled0.443509
Fofol I0.439495
Feocromocitoma Opciones estándar0.480462
Endocrinol Metab Clin0.443246
feocromocitoma metastásico cirugía0.494173
during pregnancy0.424683
feocromocitoma-paraganglioma familiar tipo0.517532
Long-term evaluation following0.440068
endocrina múltiple tipo0.439079
Pacak K0.437715
Heerden JA0.443555
with combination chemotherapy0.426625
Intern Med0.453092
autosomal dominant paraganglioma0.427278
Clin Oncol0.478285
extra suprarrenales surgen0.434497
extra suprarrenales0.652785
carney triad0.424742
feocromocitoma regional cirugía0.492979
parasimpáticos extra suprarrenales0.431253
associated with sdhb0.428378
familial paraganglioma0.44151
CLICK HERE
2053 National Cancer Institute Html es Vacunas contra los virus del papiloma humano Una hoja informativa acerca de las vacunas contra los virus del papiloma humano (VPH) para prevenir infecciones con ciertos tipos de VPH, los cuales son la causa principal del cáncer de cuello del útero o cérvix.
HPV prophylactic vaccines0.314226
hpv vaccine0.332876
Lancet Oncology0.308843
with preexisting infection0.306342
Mortality Weekly Report0.31501
bivalent hpv vaccination0.314902
largo plazo0.306588
Disease Control0.307862
genital warts among0.306064
clinical trial0.315859
anal hpv0.312394
Estados Unidos0.376477
hpv vaccination0.357231
Hariri S0.317621
Rica Vaccine Trial0.314539
PubMed Abstract0.885463
human papillomavirus0.614779
vacunas gardasil®0.319024
Infectious Diseases0.318629
quadrivalent hpv0.312783
Chaturvedi AK0.307922
BMC Infectious Diseases0.305886
hpv infection0.324228
Hildesheim A0.314688
Feng Q0.308321
among young0.314298
papillomavirus acquisition0.305662
United States0.307989
alto riesgo0.531462
Updated HPV Vaccination0.328083
British Medical Journal0.305646
HPV Vaccination Recommendations0.328083
Costa Rica0.313988
Immunization Practices0.308391
Advisory Committee0.307786
papillomavirus among0.306019
infecciones persistentes.  gardasil0.336098
9-valent human papillomavirus0.32439
papillomavirus prophylactic vaccines0.30978
Bocchini JA0.307795
¿Cuáles cánceres0.312957
Hughes JP0.308264
bivalent hpv0.331056
cuello uterino0.992097
Vaccine Safety Datalink0.314052
genital hpv infection0.315334
Cancer Institute0.307587
New England Journal0.348895
Petrosky E0.307326
CLICK HERE
15738 National Cancer Institute Html en Financial Toxicity and Cancer Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the risk of experiencing financial difficulty during cancer treatment.
adult cancer survivors0.29753
cancer treatment0.260149
study0.333877
high out-of-pocket spending0.29174
health insurance0.332995
newly diagnosed cancer0.254116
out-of-pocket cost burden0.275794
financial hardship0.814372
colorectal cancer patients0.270243
colorectal cancer survivors0.274934
economic burden0.33821
higher out-of-pocket spending0.308086
Support Care Cancer0.263278
material financial hardship0.310411
Cancer Care Outcomes0.299421
high out-of-pocket costs0.25691
health care0.364957
out-of-pocket health care0.305633
higher out-of-pocket costs0.256873
high out-of-pocket burden0.326935
State cancer patients0.282656
cancer care0.417219
personal financial burden0.365783
lung cancer patients0.262392
ongoing cancer care0.28258
colorectal cancer0.3351
cancer patients0.489203
Clin Oncol0.334879
comprehensive cancer center0.290609
cancer-related financial burden0.257868
cancer diagnosis0.320181
later financial hardship0.252008
Long-term financial burden0.276409
financial distress0.563858
out-of-pocket spending0.410176
breast cancer survivors0.328299
financial burden0.630038
out-of-pocket costs0.285058
greater financial burden0.273818
financial toxicity0.49873
cancer survivors0.880073
advanced-stage cancer patients0.289755
high financial burden0.284717
cancer0.949444
substantial financial hardship0.256681
risk0.255869
cancer history0.289124
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.